人参多糖通过调节肠道微生物群和托代谢来改善性结肠炎
Li Wan1, Cheng Qian2, Chunmei Yang2
1Department of General Surgery, Jiangsu Province Hospital of Chinese Medicine, Affiliated Hospital of Nanjing University of Chinese Medicine, Nanjing 210029, China.
International journal of biological macromolecules
|March 23, 2024
概括
人参多糖 (GPs) 通过减少结肠炎症和恢复肠道细菌平衡,在治疗性结肠炎 (UC) 中表现有前途. 这种天然化合物有效地对抗炎症反应,并加强肠道屏障.
科学领域:
- 胃肠病学 胃肠病学
- 免疫学 免疫学 免疫学
- 微生物学 微生物学
背景情况:
- 性结肠炎 (UC) 是一种慢性炎症性肠病,治疗选择有限.
- 德克斯硫酸 (DSS) 诱导的大肠炎是研究UC病变的常见模型.
研究的目的:
- 在DSS诱导的UC小鼠模型中研究人参多糖的治疗潜力.
- 阐明全科医生的抗炎和肠道保护作用背后的机制.
主要方法:
- 在小鼠中的DSS诱导性结肠炎模型.
- 对结肠病理和炎症细胞透的评估.
- 16S rRNA基因测序用于肠道微生物群分析.
- 抗生素治疗和便微生物群移植 (FMT) 实验.
- 测量炎症性细胞因子和微生物托代谢产物.
- 评估肠道的透性和屏障完整性.
- 对5-HT/HTR3A信号通路的分析.
主要成果:
- 在DSS诱导的UC小鼠中,全科医生显著改善了结肠病理性病变,并抑制了炎症性细胞因子表达.
- 全科医生的治疗抑制了炎症细胞透到结肠.
- 全科医生恢复了肠道微生物的平衡,特别是增加了乳酸菌的相对丰度.
- 医生调节了微生物托代谢物,降低了肠道透性,提高了肠道屏障的完整性.
- 这些效应部分通过抑制5-HT/HTR3A信号通路来介导.
结论:
- 人参多糖体对性结肠炎具有显著的治疗潜力.
- 一般医生通过抑制炎症,调节肠道微生物群 (特别是乳酸菌) 和恢复肠道屏障功能来发挥它们的有益作用.
- 抗炎和肠道保护机制涉及影响微生物托代谢物和5-HT/HTR3A信号通路.
相关概念视频
Drugs for Treatment of Ulcerative Colitis in IBD
138
Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs Affecting GI Tract Motility: Serotonin Receptor Agonists
252
Serotonin, a crucial neurotransmitter synthesized by enterochromaffin cells, plays a cardinal role in regulating gastrointestinal (GI) motility. With over 90% of the body's total serotonin in the GI tract, its influence on digestive processes is profound. Serotonin is swiftly released upon various stimuli, such as food boluses or certain drugs, triggering intrinsic sensory neurons in the myenteric plexus and extrinsic vagal and spinal sensory neurons. This leads to the activation of the...
252
Irritable Bowel Syndrome I: Introduction
272
Irritable Bowel Syndrome (IBS) is characterized by functional disturbances in the gastrointestinal system, presenting a cluster of symptoms without evident structural or biochemical abnormalities. It primarily affects the large intestine and may cause abdominal pain, bloating, excessive gas, diarrhea, constipation, or both.
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
IBS is a chronic condition that can persist over a long period or recur frequently.
The pathogenesis of IBS involves a complex interplay of the following factors:
Altered...
272
Inflammatory Bowel Disease III: Diagnostic Studies and Management I-Nutritional Therapy
331
Various diagnostic tests are employed in the diagnostic process for Inflammatory Bowel Disease (IBD), particularly to differentiate between Crohn's disease and ulcerative colitis.
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
Diagnostic studies
A colonoscopy is the definitive screening test, distinguishing ulcerative colitis from other colon diseases with similar symptoms. During a colonoscopy test, inflamed mucosa with exudate ulcerations can be observed, and biopsies are taken to determine the histologic characteristics of the...
331
Drugs for Treatment of Diarrhea-Predominant IBS
166
Diarrhea-predominant irritable bowel syndrome (IBS-D) is a subtype of IBS characterized primarily by frequent, loose, or watery stools, abdominal pain, and abdominal discomfort. Therapeutic approaches to managing IBS-D include dietary changes, stress management techniques, and pharmaceutical interventions.
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
Two specific drugs used in the treatment are alosetron (Lotronex) and eluxadoline (Viberzi). Alosetron, a 5-HT3 antagonist, works by slowing the movement of stools in the gut, reducing bowel...
166
Drugs Affecting GI Tract Motility: Adsorbents as Antidiarrheal Agents
210
Diarrhea is characterized by the occurrence of frequent, watery bowel movements. Various factors can trigger diarrhea, including viral or bacterial infections, foodborne illnesses, side effects from certain medications, and underlying digestive disorders. If not adequately managed, diarrhea can lead to complications such as dehydration, electrolyte imbalances, and nutrient deficiencies. Severe diarrhea can lead to significant weight loss, malnutrition, and weakened immune function.
Adsorbents...
Adsorbents...
210


